Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

578

Participants

Timeline

Start Date

November 20, 2015

Primary Completion Date

May 15, 2017

Study Completion Date

December 23, 2019

Conditions
HIV-1 Infection
Interventions
DRUG

RTV

100 mg capsule coadministered orally with ATV or DRV once daily with food

DRUG

ATV

300 mg capsule administered orally once daily with food

DRUG

DRV

800 mg tablet administered orally once daily with food

DRUG

COBI

150 mg tablet coadministered orally with ATV or DRV once daily with food

DRUG

ATV/co

300/150 mg FDC tablet administered orally once daily with food

DRUG

DRV/co

800/150 mg FDC tablet administered orally once daily with food

DRUG

FTC/TDF

200/300 mg FDC tablet administered orally once daily without regard to food

DRUG

ABC/3TC

600/300 mg tablet administered orally once daily with or without regard to food

DRUG

B/F/TAF

50/200/25 mg FDC tablet administered orally once daily without regard to food

Trial Locations (119)

935

Rio Piedras

1000

Brussels

1105

Springfield

2010

Darlinghurst

Sydney

3004

Melbourne

3068

Fitzroy

3141

Prahran

6202

Nice

9000

Ghent

10467

The Bronx

12157

Berlin

13353

Berlin

14215

Buffalo

19107

Philadelphia

20017

Washington D.C.

20036

Washington D.C.

20127

Milan

20157

Milan

20251

Hamburg

27710

Durham

27834

Greenville

28034

Madrid

28040

Madrid

28078

Huntersville

28209

Charlotte

29010

Málaga

29203

Columbia

30312

Atlanta

30912

Augusta

31201

Macon

32504

Pensacola

32720

DeLand

32960

Vero Beach

33133

Miami

33136

Miami

33305

Wilton Manors

33316

Fort Lauderdale

33401

West Palm Beach

33614

Tampa

34982

Ft. Pierce

37000

Tours

38105

Memphis

40202

Louisville

40237

Düsseldorf

44093

Nantes

45122

Essen

48072

Berkley

50924

Cologne

53127

Bonn

55407

Minneapolis

59200

Tourcoing

60590

Frankfurt

60596

Frankfurt

60613

Chicago

60657

Chicago

63139

St Louis

64111

Kansas City

66160

Kansas City

69317

Lyon

70112

New Orleans

75010

Paris

75215

Dallas

75219

Dallas

75246

Dallas

75571

Paris

75605

Longview

77004

Houston

77098

Houston

78705

Austin

80045

Aurora

80335

München

81675

München

85012

Phoenix

85015

Phoenix

90027

Los Angeles

90036

Los Angeles

90069

Los Angeles

90502

Torrance

92103

San Diego

92663

Newport Beach

94102

San Francisco

94577

San Leandro

94602

Oakland

95825

Sacramento

96813

Honolulu

98104

Seattle

99204

Spokane

32803-1851

Orlando

Unknown

Chicago

The Bronx

Santo Domingo

01211

Boston

27599-7080

Chapel Hill

22003-7313

Annandale

V6Z 2T1

Vancouver

M5G 1K2

Toronto

M5G2N2

Toronto

H2L 4P9

Montreal

H3A 1T1

Montreal

H4A 3J1

Montreal

00149

Roma

00731

Ponce

00909

San Juan

00935

San Juan

B4 6DH

Birmingham

B9 5SS

Birmingham

BN2 3EW

Brighton

EH4 2XU

Edinburgh

L7 8XP

Liverpool

E1 1BB

London

NW3 2QG

London

SE1 7EH

London

SE5 9RJ

London

SW10 9TH

London

SW17 0QT

London

W2 1NY

London

M13 0FH

Manchester

M8 5RB

Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY